# CRI-CCTG-002 (NCT04093167)

> Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04093167
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Canadian Cancer Trials Group
- Conditions: Lung Cancer
- Interventions: Pembrolizumab
- Enrollment: 53
- Primary outcome: Stage 1: Concordance rate between molecular response and radiologic response
- Primary outcome: Stage 2: Phase II Progression-Free Survival (PFS)
- Primary outcome: Stage 2: Phase III Overall Survival

## Indexed commentary on CRI-CCTG-002 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 21
- Podcasts: 5
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cri-cctg-002-nct04093167

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04093167", "email": "<work email>"}; the inbox owner confirms by the emailed link.